Viamet Pharmaceuticals
Viamet Pharmaceuticals is a venture-backed, clinical-stage biopharmaceutical company founded in 2005 in Morrisville, NC, developing small molecule metalloenzyme inhibitors primarily to treat fungal and infectious diseases, with no disclosed commercial revenue or approved product.
- Company typePrivate
- Founded2005
- HeadquartersMorrisville, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Viamet Pharmaceuticals does
Viamet Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Morrisville, North Carolina, founded in 2005 to discover and develop small molecule therapeutics. The company's platform centers on proprietary metalloenzyme inhibitor chemistry — designing small molecules that bind metal-containing enzyme active sites — applied initially to anti-infective disease, with lead assets targeting fungal infections. Viamet has historically operated as a venture-backed platform biotech, raising cumulative equity of approximately $99.6M across 12 disclosed financings between 2005 and 2016 from a syndicate that includes Hatteras Venture Partners, Novartis Venture Fund, Lilly Ventures, Astellas Venture Management, and Intersouth Partners, alongside $1.95M of non-dilutive funding from the U.S. Department of Defense in 2015 for biodefense-relevant infectious disease work.
The company runs on a venture-funded clinical development model: multi-round venture financing is used to advance proprietary small-molecule candidates through IND-enabling studies and Phase 2/3 trials toward eventual FDA approval and commercial out-licensing or partnership with larger pharmaceutical companies. Notable strategic events include a $60M Series C in October 2014 led by Hatteras Venture Partners — the company's largest capital event — and a 2022 transaction with Acacia Research, an IP-holding vehicle that typically monetizes patent portfolios, suggesting asset divestiture, patent licensing, or a wind-down scenario rather than an active commercial launch. No revenue, commercial product, or named customers are disclosed in the input; the company is pre-revenue from a product standpoint.
The lead signals point to a narrow, specialty pharmaceutical focus on antifungal therapeutics and recurrent infections, with a small headcount (11–50 employees) consistent with a Phase 2/3 sponsor model rather than a fully integrated commercial operation. The input does not name a CEO or scientific founder beyond Chairman Robert Schotzinger, nor does it disclose a post-2016 approval, partnership, or commercial milestone. Note: a separate lead-generation website branded "Viamet" and operated by Metaverde, LLC also appears in the scraped content describing medical-travel/navigation services; this is treated as an unrelated entity and is not part of Viamet Pharmaceuticals' product or revenue set based on firmographic identification.
Viamet Pharmaceuticals firmographics
Firmographics- Name
- Viamet Pharmaceuticals
- Legal name
- Metaverde, LLC
- Website
- https://viamet.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Viamet Pharmaceuticals is a venture-backed, clinical-stage biopharmaceutical company founded in 2005 in Morrisville, NC, developing small molecule metalloenzyme inhibitors primarily to treat fungal and infectious diseases, with no disclosed commercial revenue or approved product.
- Ownership category
- akta.pro rank
Viamet Pharmaceuticals industry classification
Industry- Product category
- Pharmaceutical Drug Discovery
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industry
- Small-Molecule API Process Development & Route Scouting (HLAGAHAA)
Keywords
Where Viamet Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Morrisville
- HQ country
- United States
- HQ region
- North America
Markets served
Viamet Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Lead Generation Services: The website collects user inquiries through contact forms and routes them for follow-up. The service is described as informational and lead-generation focused, with no explicit revenue model disclosed. It appears to generate value through inquiry collection rather than direct product sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Viamet Pharmaceuticals product offering
Product offeringCore offering
Viamet Pharmaceuticals discovers and develops small molecule inhibitors using a proprietary enzyme (metalloenzyme) binding approach for the treatment of various diseases. The company is a clinical-stage biopharmaceutical firm focused on identifying and advancing novel therapeutic compounds through its specialized chemistry platform, with operations spanning Morrisville, North Carolina.
Product overview
Viamet is a single-offering informational and lead-generation website operated by Metaverde, LLC. The core product is the Care Navigation and Medical Travel Checklist, which serves as a lead magnet to collect user inquiries. The website provides educational blog content covering health navigation, medical travel support, care coordination questions, wellness information, and responsible provider research. No paid products, modules, or premium tiers are offered — all content and the checklist are freely accessible informational resources.
Differentiator
Problem solved
Functional benefit
Products and services
- Small molecule metalloenzyme inhibitor drug candidates Novel small molecule therapeutic compounds discovered and developed using Viamet's proprietary enzyme (metalloenzyme) binding approach, advanced for the treatment of various diseases through internal R&D and external pharmaceutical partnerships.
Companies that use Viamet Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Viamet Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Viamet Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered parent_company and minor.
- Metaverde, LLCparent_companyMetaverde, LLC owns and operates the Viamet website. It is part of a broader network for education, media, and business development.
- MaicolminorConnected entity within a broader network for education, media, and business development.
- Maicol El FamosominorConnected entity within a broader network for education, media, and business development.
- Develop UniversityminorConnected entity within a broader network for education, media, and business development.
Recent moves6 records
Expansion highlights4 records
Viamet Pharmaceuticals competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Viamet Pharmaceuticals social profiles
Digital presenceViamet Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Viamet Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles1 record
Viamet Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds13 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Viamet Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Viamet Pharmaceuticals
What does Viamet Pharmaceuticals do?
Viamet Pharmaceuticals discovers and develops small molecule inhibitors using a proprietary enzyme (metalloenzyme) binding approach for the treatment of various diseases. The company is a clinical-stage biopharmaceutical firm focused on identifying and advancing novel therapeutic compounds through its specialized chemistry platform, with operations spanning Morrisville, North Carolina.
Is Viamet Pharmaceuticals a public or private company?
Viamet Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Viamet Pharmaceuticals founded?
Viamet Pharmaceuticals was founded in 2005. It employs 11 to 50 people.
Where is Viamet Pharmaceuticals based?
Viamet Pharmaceuticals is headquartered in Morrisville, United States, in the North America region.
How does Viamet Pharmaceuticals make money?
One revenue line is on record: lead Generation Services.
Does Viamet Pharmaceuticals have an API?
No public API is recorded for Viamet Pharmaceuticals.
What industry is Viamet Pharmaceuticals in?
Viamet Pharmaceuticals's product category is Pharmaceutical Drug Discovery. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAGAHAA, Small-Molecule API Process Development & Route Scouting. Its NAICS code is 3254 and its SIC code is 2834.